Irinotecan Accord

Irinotecan, the active ingredient in Irinotecan Accord, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is used to treat metastatic and advanced colorectal cancer in adult patients.

GNH USA supplies Irinotecan Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and specialty pharmacies worldwide.

Irinotecan is employed in the management of colorectal cancer and related disease stages.

Metastatic colorectal cancer: helps control tumor growth and prolong survival in patients with metastatic disease. Advanced colorectal cancer: provides disease stabilization and symptom relief in advanced cases. Colorectal cancer (general): used as part of combination chemotherapy regimens to improve treatment outcomes.

Irinotecan therapy is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: often delayed and can be severe. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Alopecia: hair loss during treatment cycles. - Fatigue: generalized tiredness. - Abdominal cramping: discomfort in the gastrointestinal tract.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent care. - Severe colitis: intense inflammation of the colon. - Cholinergic syndrome: sweating, lacrimation, and bradycardia. - Hepatic toxicity: elevated liver enzymes or jaundice. - Allergic reactions: rash, itching, or anaphylaxis. - Hemorrhagic cystitis: bladder inflammation with bleeding.

Prior to initiating Irinotecan therapy, clinicians should assess patient-specific risk factors and monitor for potential complications.

Monitor blood counts: perform regular complete blood counts to detect neutropenia. Assess liver function: evaluate hepatic enzymes before and during treatment. Evaluate bowel health: screen for pre‑existing gastrointestinal disorders. Use anti‑emetics: prophylactic medication can reduce nausea and vomiting. Adjust dose in renal/hepatic impairment: modify regimen based on organ function. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase SN‑38 exposure. - Enzyme inducers (e.g., rifampin): may reduce therapeutic effect. - Concurrent myelosuppressive agents: heightened risk of severe neutropenia.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): potential for altered bleeding risk. - Other antidiarrheal drugs: may mask early signs of severe diarrhea. - Drugs affecting cholinergic pathways: could exacerbate cholinergic syndrome.